Developing Low Molecular Weight PET and SPECT Imaging Agents

This article describes the general development path leading from the expression of an imaging need and project initiation to a clinically usable imaging agent. The definition of the project rationale, the design and optimization of early leads, and the assessment of the imaging potential of an imaging agent candidate are followed by preclinical and clinical development activities that differ from those required for therapeutic agents. These include radiolabeling with a positron emitter and first-in-human clinical studies, to rapidly evaluate the ability of a new imaging agent to address the questions it was designed to answer.PMID:38634545 | DOI:10.1002/cmdc.202400094

Source: ChemMedChem - April 18, 2024 Category: Chemistry Authors: Lian Xue Caitlin V M L Jie Sandrine Desrayaud Yves P Auberson Source Type: research